AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00183573 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Informational Intervention
Description: 4-hour, information-only intensive group workshop
Study NCT00494065 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chiropractic Spinal Manipulative Therapy + Home exercise
Description: The number and frequency of treatments will be determined by the individual chiropractor, based on patient-rated symptoms, disability, palpation, and pain provocation tests. Up to 20 treatments will be provided over the 12 week treatment period, each treatment visit lasting from 10-20 minutes. Treatment will include manual spinal manipulation and mobilization.
Study NCT03052764 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: onabotulinumtoxinA
Description: OnabotulinumtoxinA (BOTOX®) injection into the bladder.
Study NCT03052764 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: onabotulinumtoxinA
Description: OnabotulinumtoxinA (BOTOX®) injection into the bladder.
Study NCT03052764 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (saline)
Description: Placebo (saline) injection into the bladder.
Study NCT00183573 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Info-Motivation-Behavioral Skills Intervention
Description: 4-hour, intensive group workshop with emphasis on motivation and skills
Study NCT00415155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2181308
Description: Phase 1: 250mg, IV, loading dose days 1-3 cycle 1 then weekly for six 28 day cycle. (dose escalation)~Phase 2: phase 1 recommended dose, maximum 750mg dose, IV, loading dose days 1-3 cycle 1 then weekly for six 28 day cycle.
Study NCT02474615 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ENDODONTIC SURGERY
Description: ENDODONTIC SURGERY
Study NCT03074981 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combined TopClosure & Vcare Alpha
Description: Combined TopClosure \& Vcare Alpha Treatment. The investigators will debride the wound if necessary. Wound biopsies will be taken to determine the existing pathogens and direct the antibiotic treatment.~Wound measurements will be taken. Afterwards the wound will be approximated by the TopClosure device and the patient will be connected to a Negative Wound pressure device Vcare Alpha.~The investigators will change dressings according to schedule. If the wound is clean the investigators will change dressings every 3-5 days, If the wound is infected the investigators will change dressings every 2-4 days, If the investigators encounter a severe infected wound with a lot of pus the investigators will change dressings every 1-3 days, The investigators will determine the time to heal when the wound is clean and there is no further need for Negative Pressure Wound Treatment (ROI-NPT) up to 10 weeks.
Study NCT01897857 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: duplex Doppler ultrasonography
Study NCT01897857 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: duplex Doppler ultrasonography
Study NCT05724212 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Interferon gamma release assay (IGRA)
Description: in vitro test
Study NCT03352050 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: mushroom
Study NCT03150485 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: JJVC Fitting Guides
Description: Subjects who are habitual contact lens wearers with Presbyopic correction or Presbyopic symptoms, at least 40 years of age and no more than 70 years of age, will be fitted, according to the fitting guides, with either the Multifocal Contact Lens or an Toric Multifocal Contact Lens if refractive cylinder power of the eye is between -1.00 to -1.50. The Intervention is approximately 30-90 minutes of wear time during a 1-day visit.
Study NCT00017316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaxanib
Study NCT03150485 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JJVC Fitting Guides
Description: Subjects who are habitual contact lens wearers with Presbyopic correction or Presbyopic symptoms, at least 40 years of age and no more than 70 years of age, will be fitted, according to the fitting guides, with either the Multifocal Contact Lens or an Toric Multifocal Contact Lens if refractive cylinder power of the eye is between -1.00 to -1.50. The Intervention is approximately 30-90 minutes of wear time during a 1-day visit.
Study NCT03319667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab SAR650984
Description: Pharmaceutical form: Solution for infusion~Route of administration: Intravenous (IV)
Study NCT03319667 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Isatuximab SAR650984
Description: Pharmaceutical form: Solution for infusion~Route of administration: Intravenous (IV)
Study NCT03319667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Pharmaceutical form: Lyophilized powder for injection~Route of administration: Subcutaneous
Study NCT03319667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Pharmaceutical form: Lyophilized powder for injection~Route of administration: Subcutaneous
Study NCT03319667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Pharmaceutical form: Capsules~Route of administration: Oral
Study NCT03319667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Pharmaceutical form: Capsules~Route of administration: Oral
Study NCT03319667 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lenalidomide
Description: Pharmaceutical form: Capsules~Route of administration: Oral
Study NCT03319667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Pharmaceutical form: Tablets, ampoules or vials for injection~Route of administration: Oral/Intravenous
Study NCT03319667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Pharmaceutical form: Tablets, ampoules or vials for injection~Route of administration: Oral/Intravenous
Study NCT03319667 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dexamethasone
Description: Pharmaceutical form: Tablets, ampoules or vials for injection~Route of administration: Oral/Intravenous
Study NCT04024878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab (Opdivo®) is an antibody. An antibody is a common type of protein produced by the body that the immune system uses to find and destroy foreign molecules.
Study NCT00017316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Study NCT03468283 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobile application for diabetes
Description: Intervention was mobile application and individualized regular message feedback sent by healthcare professionals.
Study NCT03999567 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pen and Paper Digit Symbol Substitution Test (DSST)
Description: The DSST is a paper-and-pencil cognitive test presented on a single sheet of paper that requires a subject to match symbols to numbers according to a key located on the top of the page. The subject copies the symbol into spaces below a row of numbers. The number of correct symbols within the allowed time, usually 90 to 120 seconds, constitutes the score.
Study NCT04024878 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeoVax
Description: The vaccine will consist of up to 20 peptides as well as a drug that activates the immune system called Poly-ICLC. Poly-ICLC (also called Hiltonol) is an experimental viral mimic and an activator of immunity
Study NCT04024878 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Core Needle Biopsy
Description: Surgical procedure
Study NCT03999567 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Digit Symbol Substitution Test (DSST)- (a.k.a. Codebreaker)
Description: Code breaker is the mobile/electronic version of the pen and paper DSST which is capable of identifying deficits in the domains of executive function, processing speed and attention/concentration, and takes 2 minutes to complete. Six symbols are numbered consecutively. Users are presented with a series of numbers that they must then match with the correct corresponding symbol as quickly as possible. Users are scored on speed and accuracy.
Study NCT01958606 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIT)
Description: Treadmill exercise using bursts of concentrated effort alternated with recovery periods
Study NCT01958606 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Aerobic Training
Description: Moderate intensity continuous aerobic exercise on a treadmill
Study NCT01848821 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: OASIS Ultra
Description: Porcine derived intestinal submucosa
Study NCT01678937 — intervention group
Intervention type: PROCEDURE
Intervention: Blood Draw - Rapamycin
Description: Ten calcineurin-inhibitors (CNI) monotherapy or dual therapy (CNI+MMF) patients will have blood taken (40 ml=8 tsp.) 2 wks. prior to conversion, 3-6 months post successful conversion. 1) Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28-FOXP3+CD127low cells). 2) Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers shown to induce regulatory T cells (ILT3; ILT4), 3) Soluble HLA G, and 4) Liver function/drug levels. If problems develop during conversion (e.g. acute rejection, significant drug side effects) requiring discontinuation of rapamycin, MMF and/or reversion to CNI therapy, assays will not be performed. Monthly liver function/drug levels performed after successful conversion (standard of care).
Study NCT01678937 — intervention group
Intervention type: PROCEDURE
Intervention: Blood Draw from Control Subjects
Description: Ten healthy individuals will have blood drawn (40 ml = 8 teaspoons (tsps.)).Blood will be drawn at one time point for the following:~* Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).~* Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells).~* HLA microchimerism \& HLA G
Study NCT01678937 — intervention group
Intervention type: PROCEDURE
Intervention: Blood Draw - CyA
Description: Blood drawn from 10 patients on cyclosporine (CyA) (40 ml = 8 tsp.)). Blood will be drawn at one time point for the following:~* Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).~* Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells).~* HLA microchimerism \& HLA G
Study NCT01678937 — intervention group
Intervention type: PROCEDURE
Intervention: Blood Draw - Tacrolimus
Description: Blood drawn from 5 patients on Tacrolimus (40 ml = 8 tsp.) at one time point for the following:~* Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).~* Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells).~* HLA microchimerism \& HLA G
Study NCT01678937 — intervention group
Intervention type: PROCEDURE
Intervention: Blood Draw - MMF
Description: Blood will be drawn from 10 patients on mycophenolate mofetil (MMF) (40 ml or the equivalent of 8 teaspoons). Blood will be drawn at one time point for the following analysis:~* Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).~* Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells).~* HLA microchimerism \& HLA G
Study NCT01678937 — intervention group
Intervention type: PROCEDURE
Intervention: Blood Draw - Rapamycin
Description: Blood drawn from 10 patients on rapamycin (40 ml = 8 tsp.)) at one time point for the following:~* Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).~* Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells).~* HLA microchimerism \& HLA G
Study NCT03645031 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Intermittent Hypoxia
Description: AIH entails continuous breathing as the level of oxygen in the air is decreased, then returned to normal. Participants will alternate between breathing normal air and breathing hypoxic air (air that has less oxygen). Participants will complete a single 45 minute session of acute intermittent hypoxia (AIH). Breathing, muscle activity and heart activity will be monitored before, during and after the procedure. The intervals will last 1 minute each.
Study NCT03645031 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Acute Intermittent Hypoxia
Description: Participants will complete the sham acute intermittent hypoxia, consisting of a single 45 minute session of breathing air with normal oxygen levels. All aspects of this procedure will otherwise be the same as for the AIH procedure. Breathing, muscle activity and heart activity will be monitored before, during and after the procedure.
Study NCT00255801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Targretin® (bexarotene)
Study NCT00255801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin hydrochloride
Study NCT02583191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Rivaroxaban 15 mg twice daily for 21 days, followed by 20 mg once daily over a period of 3 months
Study NCT02583191 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: low-molecular heparine
Description: LMWH in therapeutic dosage (1-2× daily s.c.) according to standards of the individual study center, using licensed dosages, e.g.~* Enoxaparin 1 mg/kg BW twice daily~* Tinzaparin 175 I.E./kg BW once daily~* Dalteparin 200 I.E./kg BW once daily
Study NCT02128516 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral powder in sachet
Study NCT01158508 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Description: Transient lower limb ischemia will be induced by inflation of a blood pressure cuff on the thigh. Four five minute cycles of ischemia will be performed, each followed by five minutes of reperfusion with the cuff down. This procedure will be performed in four rounds, typically on post-hemorrhage days 2, 3, 6 and 9.
Study NCT01848821 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Wound VAC Standard Therapy
Description: Negative pressure wound device aka wound VAC will be placed on the standard therapy half of the wound
Study NCT00992446 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo ASCT
Study NCT00992446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given IV
Study NCT02128516 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: oral powder in sachet
Study NCT00992446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Given IV
Study NCT00992446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT00992446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT00992446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV
Study NCT00992446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT00992446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO
Study NCT02128516 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: oral powder in sachet
Study NCT03306706 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whole pea muffins
Description: 2 muffins containing whole peas
Study NCT03306706 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Split pea muffins
Description: 2 muffins containing split peas
Study NCT03306706 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Wheat muffins
Description: 2 muffins containing wheat
Study NCT02772484 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HS-1000
Study NCT00446589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibandronate
Description: iv 1mg ibandronate monthly for one year
Study NCT00446589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teriparatide
Description: sc injection using a pen like device during every hemodialysis session (thrice a week)
Study NCT02262052 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MRDTI
Description: MRDTI is primary diagnostic test for management of suspected ipsilateral DVT
Study NCT03791827 — intervention group
Intervention type: DRUG
Intervention: Corticosteroid
Description: corticosteroid is given to patients orally or methylprednisone is given to patients through i.v.
Study NCT03791827 — intervention group
Intervention type: DRUG
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine is recommended as the basic therapy for lupus nephritis
Study NCT03791827 — intervention group
Intervention type: DRUG
Intervention: Cyclophosphamide
Description: The typical therapy for cyclophosphamide is either 500 to 750mg/m2 once every month for 6 doses or 8 to 12 mg/kg/d for two consecutive days every two weeks for 6 to 8 doses through i.v.
Study NCT03791827 — intervention group
Intervention type: DRUG
Intervention: Mycophenolate Mofetil
Description: The recommended dose of mycophenolate mofetil is 20 to 30mg/kg/d
Study NCT03791827 — intervention group
Intervention type: DRUG
Intervention: Azathioprine
Description: The recommended dose of azathioprine is 1.5 to 2mg/kg/d
Study NCT03791827 — intervention group
Intervention type: DRUG
Intervention: Tacrolimus
Description: The recommended dose of tacrolimus is 0.05 to 0.15mg/kg/d, Q12h
Study NCT03791827 — intervention group
Intervention type: DRUG
Intervention: Cyclosporine A
Description: The recommended initial dose of cyclosporine A is 4 to 6mg/kg/d, Q12h
Study NCT03791827 — intervention group
Intervention type: DRUG
Intervention: Rituximab
Description: The recommended dose of rituximab is 375mg/m2 once a week for 2 to 4 doses
Study NCT01557894 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iSOFIE
Description: Cognitive - Behavioral: Internet-administrated CBT for social phobia that contains 9 self-help text modules and exercises (i.e., behavioral experiments)
Study NCT03277521 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent theta burst stimulation
Description: Intermittent theta burst stimulation (iTBS) is a non-invasive brain stimulation technique that can increase corticomotor excitability.
Study NCT00674778 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Any percutaneous cardiovascular procedure
Study NCT00674778 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Any percutaneous cardiovascular procedure
Study NCT00929812 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon hydrochloride (GlucaGen®)
Description: 1 mg/1 ml of glucagon hydrochloride intramuscularly
Study NCT00929812 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0.9%
Description: 1 ml NaCl 0.9% intramuscularly
Study NCT02902796 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal cord stimulator
Description: Spinal cord stimulator will be programmed to deliver, according to the randomization status of the patient, burst, 1000 hertz, and standard stimulation during each treatment group.
Study NCT01788176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic acid
Description: One single dose of 5mg intravenous infusion of zoledronic acid (interventional group)
Study NCT01788176 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one single intravenous infusion of 100ml of saline.
Study NCT05730634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 Mg Oral Tablet
Description: Atorvastatin 40mg once daily for three months
Study NCT02732717 — intervention group
Intervention type: OTHER
Intervention: ultrasound (observation)
Description: Important sonographic indices are to be collected from 11-14 weeks, 16-18 weeks, 22-24 weeks, 30-32 weeks and 37-39 weeks,including crown-rump length, nuchal translucency, amniotic fluid, umbilical artery flow, middle cerebral artery flow,ductus venous flow. It is observational.~Conditions as below are thought abnormal: discordance of crown-rump length more than 20%, discordance of nuchal translucency more than 20%, either of twin with abnormal amniotic fluid (polyhydramnios or oligoamnios), either of twin with abnormal umbilical artery flow (elevated resistance index, absent or reverse diastolic flow), either of twin with abnormal middle cerebral artery flow (more than 1.5Mom), either of twin with abnormal ductus venous flow (absent or reverse a-wave).
Study NCT03022227 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telemedicine
Description: telemedicine applied to adult cochlear implant users' follow-up
Study NCT03022227 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: telemedicine
Description: telemedicine applied to adult cochlear implant users' follow-up